Ataraxis AI

Ataraxis AI released CTX, a causal multi-modal model that predicts the five-year recurrence-free gain from adding chemotherapy for HR+/HER2− breast cancer patients from routine pathology slides and clinical variables, rather than recurrence risk alone. Across 1,994 held-out patients from five cohorts in three countries, the treatment-by-biomarker interaction for CTX-τ was significant (p=2.1×10⁻⁶), and in the held-out phase 3 trials TAILORx and UNIRAD it separated patients who benefit from chemotherapy from those who may need treatment escalation.

Ataraxis AI released CTX, a causal multi-modal model that predicts the five-year recurrence-free gain from adding chemotherapy for HR+/HER2− breast cancer patients from routine pathology slides and clinical variables, rather than recurrence risk alone. Across 1,994 held-out patients from five cohorts in three countries, the treatment-by-biomarker interaction for CTX-τ was significant (p=2.1×10⁻⁶), and in the held-out phase 3 trials TAILORx and UNIRAD it separated patients who benefit from chemotherapy from those who may need treatment escalation.